University of Buenos Aires
Argentina | 1980 | Ph.D.
Downers Grove, IL
HISTORY OF CURRENT AND PREVIOUS ACADEMIC/PROFESSIONAL APPOINTMENTS
2000-current Professor, Department of Pharmacology, College of Graduate Studies, Chicago College of Osteopathic Medicine, Chicago College of Pharmacy, College of Dental Medicine Illinois, Chicago College of Health Science, Chicago College of Optometry, Midwestern University, Downers Grove, Illinois
1995-2000 Associate Professor, Department of Pharmacology, Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, Illinois
1993-1995 Assistant Professor, Department of Pharmacology, Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, Illinois
1990-1993 Research Assistant Professor, Department of Physiology, Louisiana State University Medical Center, New Orleans, Louisiana
1988-1990 Research Scientist, National Academy of Medicine and National Research Council, Buenos Aires, Argentina
1987-1988 Adjunct Assistant Professor, Department of Biology, University of California Santa Barbara, Santa Barbara, California
1985-1987 Postdoctoral Fellow, Department of Biology, University of California Santa Barbara, Santa Barbara, California
Downers Grove, IL
Chicago College of Optometry
Chicago College of Osteopathic Medicine
College of Dental Medicine-Illinois
College of Graduate Studies - IL
SYNOPSIS OF TEACHING EXPERIENCE AND EDUCATIONAL PROGRAM RESPONSIBILITIES (1993-2021)
During the past 27 years, as a faculty member of the Department of Pharmacology at the College of Graduate Studies (CGS), my teaching responsibilities have included lectures and clinical case studies to students from Chicago College of Osteopathic Medicine (CCOM), Chicago College of Pharmacy (CCP), Chicago College of Health Sciences (CHP), College of Dental Medicine Illinois (CDMI) and Chicago College of Optometry (CCO), in the following areas as classified in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition: Drugs acting on the central nervous system: local anesthetics; Autacoids: drug therapy of inflammation: nonsteroidal anti-inflammatory agents, corticosteroids and drugs used for the treatment of arthritis; Chemotherapy of microbial diseases: drugs for used in the treatment of tuberculosis and leprosy, antivirals (including anti-HIV agents), and antifungal agents; Chemotherapy of neoplastic diseases: antineoplastic agents; Drugs used for immunomodulation: immunosuppressive and immune stimulant agents; Drugs acting on the blood and blood forming organs: hematopoietic agents, anticoagulant, thrombolytic and antiplatelet drugs; Hormones and Hormone Antagonists: adrenocortical steroids and synthetic analogs. I have served as Course Director of CCOM/CCP/CHS/CCO Pharmacology courses in numerous years. In addition, from 1994-2011, I contributed a two-hour Marine Pharmacology lecture to CCP students participating in the Topics in Advanced Medicinal Chemistry course. Finally, I have served as the course Director of a 20-hour Medical Spanish elective, which has been offered during the Fall and Spring quarters to medical, pharmacy and health science students from 1994-2017.
Marine pharmaceuticals: marine natural products as pharmacological agents for the modulation of inflammatory and neurotoxic mediators generated by activated microglia Neuroinflammatory conditions are complex and poorly understood disease processes which are hypothesized to involve microglia or brain macrophages. When microglia become activated they release cytotoxic substances (reactive oxygen intermediates, eicosanoids, cytokines and metalloproteinases) which are cytotoxic to brain cells. Microglia are believed to be involved in human brain disorders, such as postischemic brain injury, HIV encephalopathy, Parkinson's disease, Alzheimer's disease and multiple sclerosis. Present therapies of these inflammatory conditions are based on steroids and nonsteroidal anti-inflammatory therapies which are associated with a high incidence of unsatisfactory toxicity and poor efficacy. Marine anti-inflammatory natural products may constitute a novel source of lead compounds to enable the development of a new generation of drugs for the clinical management of neurological diseases. The Mayer lab which has been studying marine natural products at CCOM for the past 27 years, has become a contributor to the discovery of novel marine antineuroinflammatory compounds, and has contributed the first two patents assigned to Midwestern University (US patents # 6,3887,916 and # 6,602,881) in 2002 and 2003, respectively. Dr. Mayer's marine pharmaceutical's website maintained with the assistance of CCP students and the IT Department is currently # 1 in Google and has been visited over 49,000 times. Dr. Mayer served as the Editor-in-Chief of the journal Marine Drugs from January 2014 till July 2018.
Marine toxicology: immunotoxicology of marine and freshwater-derived cyanobacterial lipopolysaccharides. Cyanobacteria or blue-green algae, are photosynthetic prokaryotes that represent one of the oldest life forms and are a rich source of natural products with unique pharmacological and toxicological properties, which possess neuroprotective, cytotoxic, antibacterial, antifungal, antiviral and anti-inflammatory properties. Cyanobacterial LPS differs from Gram-negative bacteria both chemically and biologically. The Mayer lab has been studying the immunotoxicology of cyanobacterial lipopolysaccharides since 2011 and has shown that the cyanobacterial LPS’s elicit release of superoxide anion, thromboxane B2, cytokines, chemokines, and matrix metalloproteinase-9 by rat microglia in vitro.
Recent list of publications
Z. Memedovski, E. Czerwonka, J. Han, J. Mayer, M. Luce, L. C. Klemm, M. L. Hall, and A.M.S. Mayer. Classical and Alternative Activation of Rat Microglia treated with ultrapure Porphyromonas gingivalis Lipopolysaccharide in vitro. Prepared for submission, April 2020.
Mayer, A.M.S., A.J. Guerrero, A. D. Rodríguez, O. Taglialatela-Scafati, F. Nakamura and N. Fusetani. Marine Pharmacology in 2014–2015: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis, and Antiviral Activities; Affecting the Immune and Nervous Systems, and other Miscellaneous Mechanisms of Action. Marine Drugs 18(5), 2019. PMID: 31861527
Swanson-Mungerson, M., P. Williams, J. Gurr, R. Incrocci, V. Subramaniam, K. Radowska, M. L. Hall, and A.M.S. Mayer. Biochemical and Functional Analysis of Cyanobacterium Oscillatoria sp. LPS on Human Monocytes. Toxicological Sciences 171(2):421-430, 2019. PMID: 31271425
L. C. Klemm, E. Czerwonka, M. L. Hall, P. Williams, and A.M.S. Mayer. Cyanobacteria Scytonema javanicum and Scytonema ocellatum lipopolysaccharides elicit release of superoxide anion, matrix-metalloproteinase-9, cytokines and chemokines by rat microglia in vitro. TOXINS 10: 130, 2018. PMID: 29561785
Mayer, A.M.S., A. D. Rodríguez, O. Taglialatela-Scafati and N. Fusetani. Marine Pharmacology in 2012-2013: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis, and Antiviral Activities; Affecting the Immune and Nervous Systems, and other Miscellaneous Mechanisms of Action. Marine Drugs 15 (9): 273, 2017. PMID: 28850074
M. Swanson-Mungerson, R. Incrocci, V. Subramaniam, P. Williams, M. L. Hall, and A.M.S. Mayer. Effects of cyanobacteria Oscillatoria sp. lipopolysaccharide on B cell activation and Toll-like receptor 4 signaling. Toxicology Letters 275: 101-107, 2017. PMID: 28499610
Mayer, A.M.S., J. Murphy, D. MacAdam, C. Osterbauer, I. Baseer, M. L. Hall, D. Feher and P. Williams. Classical and alternative activation of cyanobacterium Oscillatoria sp. lipopolysaccharide-treated rat microglia in vitro. Toxicological Sciences 149(2):484-95, 2016.
Avilés, E, Prudhomme, J., Le Roch, K.G., Franzblau, S.G., Chandrasena, K., Mayer, A.M.S., and A.D. Rodríguez. Synthesis and preliminary biological evaluation of a small library of hybrid compounds based no Ugi isocyanide multicomponent reactions with a marine natural product scaffold. Bioorganic & Medicinal Chemistry Letters 25(22):5339-43, 2015
Mayer, A.M.S., M. L. Hall, M. Holland, C. De Castro, A. Molinaro, M. Aldulescu, J. Frenkel, L. Ottenhoff, D. Rowley and J. Powell. Vibrio vulnificus M06-24/O lipopolysaccharide stimulates superoxide anion, thromboxane B2, matrix metalloproteinase-9, cytokine and chemokine release by rat microglia in vitro. Marine Drugs 12:1732-1756, 2014.
C. Jiménez-Romero, A.M.S. Mayer and A.D. Rodríguez. Dactyloditerpenol acetate, a new prenylbisabolane-type diterpene from Aplysia dactylomela with strong anti-neuroinflammatory activity. Bioorganic & Medicinal Chemistry Letters 24: 344-348, 2014.
2016 Member: IUPHAR, International Union of Basic and Clinical Pharmacology
2015 Member: Council of Scientific Editors
1994 Member: American Society for Pharmacology and Experimental Therapeutics
1991 Member: American Association for the Advancement of Science
Resubmission of R15 Grant Proposal titled: Cyanobacterial LPS and brain microglia activation
In order to resubmit this R15 Grant proposal with a new approach as requested by the NIH Study Section reviewers, we have been working to establish cultures of de-identified human brain tissue provided by Cook County Hospital and developing methods to isolate microglia from human brain cultures. So far my laboratory at MWU has received 4 de-identified human brain tissue biopsies from Dr. Sierens, at the John J. Stroger Jr., Hospital of Cook County, Chicago. The de-identified human brain biopsies received were placed in tissue culture. Interestingly, 3 of 4 brain biopsies developed into cell cultures, which are currently growing in my laboratory in Science Hall 308, Midwestern University Downers Grove campus. In the summer of 2018, Tina Moazezi, CCOM 2021, KAS summer fellow in Dr. Mayer’s lab identified the cells types in one of the human brain tissue cultures by immunohistochemistry. In the summer of 2019, Zylfi Memedovski CCOM 2022, continued to work to confirm the presence of human microglia in one of the brain cultures using three microglia-specific antibodies. If presence of human microglia is confirmed, we plan to resubmit our R15 Grant Proposal with a revised approach based on the human microglia model.
Agency: MWU’s One Health Stimulus Research Award
Amount: Total: $10,000
Principal Investigator: Michelle Swanson-Mungerson
Co- Principal Investigator: Mayer, Alejandro
Status: Submitted: 3/18/2016. Funded on 4/19/2016
OTHER GRANT PROPOSALS
Agency: NIH P50 Program Project Grant with University of Mississippi & Henry Ford Health System
Amount: Total: $1,182,660 over 5 years. $793,730 (direct), $388,930 (indirect).
Principal Investigator: Dr. Frederick Valeriote, Henry Ford Health System
Co-Investigator: Mayer, Alejandro
Status: Submitted: 6/6/2014. Grant proposal was reviewed but unscored (12/2014).
Agency: NIH R15
Dates: April 2015 – March 2017
Principal Investigator: Gulati, Anil
Co-Investigator: Mayer, Alejandro
Status: Submitted: 6/25/2014. Grant proposal was reviewed but unscored (12/2014).
Agency: NIH R15
Amount: $340,362 (direct), $122,500 (indirect)
Total: $462,862 For MWU: $322,500
Principal Investigator: Mayer, Alejandro (PI)
Co-Investigator: Berry, John (co-PI)
Florida International University
Status: Scored 49, March 2012. Resubmitted after complete revision on 11/ 2013. Not scored.
Editor-in-Chief, MARINE DRUGS ejournal, 1/2014 to 7/31/2018
Associate Editor, MARINE DRUGS ejournal, 8/2008 to 12/2013
President, Great Lakes Chapter of the American Society of Pharmacology and Experimental Therapeutics, 2011-2013
Vice-President, Great Lakes Chapter of the American Society of Pharmacology and Experimental Therapeutics, 2009-2010
Faculty Representative, Midwestern University, Faculty Advisory Committee, Illinois Board of Higher Education 2013-2016
Pharmacology of Natural Products Section, IUPHAR (International Union of Basic and Clinical Pharmacology), member, March 2016
July 2016. GLC-ASPET Outstanding Contribution and Dedicated Service Award, in grateful appreciation for eight years of outstanding contribution and Dedicated Service, 2007-2015, July 2016.
June 2013. GLC-ASPET Outstanding Service Award, in appreciation for work and dedication as President of GLC-ASPET 2011-2013.
May 2011. The Littlejohn Faculty Award, honoring values of service, caring and commitment to Midwestern University.
PATENTS (FIRST TWO PATENTS FOR MIDWESTERN UNIVERSITY)
1. A. Mayer, S.P. Gunasekera, S.A. Pomponi and S.H. Sennett. Anti-inflammatory uses of the Manzamines. United States Patent No.: US 6,387,916, issued May 14, 2002.
2. A. Mayer, S.P. Gunasekera, S.A. Pomponi and S.H. Sennett. Anti-inflammatory uses of the Manzamines. United States Patent No.: US 6,602,881 issued Aug. 5, 2003.
My own research in marine pharmacology and pharmaceuticals, as well as that of the global marine pharmacology and pharmaceutical community, is highlighted at Home | Mysite (marinepharmacology.org) . This website has received over 49,000 hits (3/31/2021), is currently # 1 in Google search engine using the key words “ marine pharmacology” and is being constantly updated with the contributions from the global marine chemistry, pharmacology and pharmaceutical research community, as well as students from the Chicago College of Pharmacy.
INVITED SEMINARS AND LECTURES (Since 2008)
I have been honored to present marine pharmaceuticals lecture/seminar presentation that covers: (1) FDA-approved marine pharmaceuticals, (2) the clinical pipeline; and, (3) the preclinical pipeline (marine natural products with antitumor and cytotoxic activity, as well as other pharmacological activities) at several scientific meetings and universities in the USA, Argentina, Brazil, Canada, France, Germany, Greece, Italy, Mexico and South Africa, as shown below.
2019 Mayer, A.M.S. The Marine Pharmaceutical Pipeline in 2019. 5th IUPHAR World Conference of the Pharmacology of Natural Products and 51st Annual Conference of the Indian Pharmacology Society, Hyderabad, India. December 5-7, 2019.
2019 Mayer, A.M.S. The Marine Pharmaceutical Pipeline in 2019. International Summer School on Natural Products (ISSNP), Univerity of Naples “Federico II”, Naples, Italy. July 1-4, 2019.
2018 Mayer, A.M.S. The Marine Pharmaceutical Pipeline in 2018. School of Pharmacy and Pharmaceutical Sciences, Department of Pharmacology and Scripps Institution of Oceanograph, San Diego, California. April 25.
2017 Mayer, A.M.S. The Marine Pharmaceutical Pipeline in 2017. 10th European Marine Natural Products Meeting, Kolymbari, Crete, Greece. September 7.
2016 Mayer, A.M.S. The Marine Pharmaceutical Pipeline in 2016. Technische Universität Bergakademie Freiberg, Freiberg, Germany. May 18.
2016 Mayer, A.M.S. Biotechnology and the Marine Pharmaceutical Pipeline in 2016. Fundación Farmacal, A.C., La Paz, Baja California Sur, Mexico. April 20-23.
2015 Mayer, A.M.S. Biotechnology and the Marine Pharmaceutical Pipeline in 2015. National Academy of Medicine, Buenos Aires, Argentina. June 12.
2014 Mayer, A.M.S. The global marine clinical and preclinical pipeline. 17th World Congress of Basic and Clinical Pharmacology, IUPHAR Natural Products Section Symposium, Cape Town, South Africa. July 13-18.
2014 Mayer, A.M.S. The global marine pharmaceutical pipeline. Department of Pharmaceutical Sciences, Southern Illinois University Edwardsville, Illinois. November 14.
2013 Mayer, A.M.S. The global marine pharmaceutical pipeline. Department of Molecular Therapeutics and Pharmacology, Loyola University Medical Center, Maywood, Illinois. February 20.
2012 Mayer, A.M.S. The global marine pharmaceutical pipeline. Department of Cellular and Molecular Pharmacology, Rosalind Franklin University of Medicine and Science, The Chicago Medical School, North Chicago, Illinois. August 22.
2012 Mayer, A.M.S. The global marine pharmaceutical pipeline. OECD Global Forum on Biotechnology: Marine Biotechnology - Enabling Solutions for Ocean Productivity and Sustainability. Sponsored by Organization for Economic Co-operation and Development (OECD). Wosk Centre for Dialogue, Vancouver, Canada. May 30-31.
2012 Mayer, A.M.S. The global marine pharmacology preclinical pipeline. ASPET Symposium: “ Clinical Pipeline of Marine Pharmaceuticals: The Odyssey Continues” sponsored by The Division for Drug Discovery, Development and Regulatory affairs from the American Society of Pharmacology and Experimental Therapeutics, Experimental Biology 2012, San Diego, California. April 25.
2012 Mayer, A.M.S. Marine pharmacology and the global pharmaceutical pipeline. Associated Colleges of the Chicago Area Spring Seminar Series. Benedictine University, Illinois. March 13.
2011 Mayer, A.M.S. The global marine pharmaceutical pipeline. Station Biologique de Roscoff, CNRS, Roscoff, France. September 1.
2011 Mayer, A.M.S. The global marine pharmaceutical pipeline. Annual Workshop on Marine Biotechnology. Station de Biologie Marine, Museum National D’Histoire. Roscoff, France. September 1. Concarneau, France. August 31.
2011 Mayer, A.M.S. The global marine pharmaceutical pipeline. Department of Chemistry, U University of Louisiana, Monroe, Louisiana. February.
2010 Mayer, A.M.S. Marine Biodiversity and Drug Development from Marine Sources. Instituto Nacional de Tecnologia Industrial, Buenos Aires, Argentina. November 12.
2010 Mayer, A.M.S. The global marine pharmaceutical pipeline. Department of Biological Sciences, Benedictine University, Lisle, Illinois. October 13.
2010 Mayer, A.M.S. The global marine pharmaceutical pipeline. Dipartimento di Chimica delle Sostanzi Naturali, Universita Degli Studi Di Napoli Federico II, Naples, Italy. May 21.
2010 Mayer, A.M.S. The global marine pharmaceutical pipeline. Department of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois. March 17.
2009 Mayer, A.M.S. The global marine pharmacology pipeline. Chemistry Institute of São Carlos, University of São Paulo at São Carlos, Brazil. November 23.
2009 Mayer, A.M.S. The global marine pharmacology pipeline. Experimental Biology 2009. American Society of Experimental Pharmacology and Therapeutics (ASPET) Symposium: A Renaissance in Marine Pharmacology: Preclinical Curiosity to Clinical Reality. New Orleans, Louisiana. April 19.
2009 Mayer, A.M.S. Marine Pharmacology: FDA-approved marine drugs, and the marine clinical and preclinical pipeline. Florida International University, Graduate School and Marine Sciences Program. Miami, Florida. January 30.
2008 Mayer, A.M.S. Marine Pharmacology: A Critique of the Preclinical and Clinical Literature. University of Puerto Rico, Rio Piedras Campus, Department of Chemistry, San Juan, Puerto Rico. January 28.